Blood Cancer United's purchase of Luvelta keeps a compassionate use program alive for a small group of pediatric patients and exposes the structural gap that made the purchase necessary in the first place.
A small group of children — approximately 20 new patients a year, diagnosed with a rare form of acute myeloid leukemia — had been receiving an experimental drug called Luvelta through a compassionate-use program, and some of them had responded. Then Sutro Biopharma, the drug's original developer, decided in March 2025 to reprioritize its pipeline. The IND went with the development decision, and the access program ended with it. The children who were already on therapy had no automatic legal mechanism to keep the supply flowing. U.S. drug regulation, as this publication's analysis of the compassionate-use regulatory architecture finds, does not include one.
On June 11, 2026, Blood Cancer United, the patient-advocacy nonprofit formerly known as the Leukemia & Lymphoma Society, said it would buy the remaining supply of Luvelta (luveltamab tazevibulin) and take over the compassionate-use program, distributing the drug at no cost to eligible pediatric patients while supplies last, according to STAT News. The transfer of the IND turns the charity into, effectively, the steward of an investigational therapy. That is a role the U.S. drug-development system does not assign to anyone by default, and the case that produced it is not theoretical. A commercial decision by a single sponsor ended a treatment that was working for a defined group of children.
This is the actual story. A patient-advocacy organization has been forced into a pharmaceutical logistics job because the regulatory architecture for compassionate use was not built to handle a sponsor walking away. When a company decides to discontinue an investigational program, its compassionate-use cohort disappears with it. There is no public mechanism that preserves drug supply, no automatic handoff to a third party, and no obligation to transfer the IND to anyone willing to keep treating patients already on therapy. The original developer had the legal right to shelve the program. The children on it had no legal standing to keep it open.
Blood Cancer United is filling the gap with donations and volunteer coordination, not with a sustainable economic model. The supply it is buying is finite. The nonprofit is not restarting the clinical development program, and it is not asking the FDA to expand the indication. It is running a stopgap, and the people running it are explicit about the limits. The Orphan Drug Act, designed to incentivize development of therapies for rare diseases, does not solve this problem. It addresses the front end of the pipeline, not the back end, where a viable drug is discarded for commercial reasons after patients have already been exposed to it.
Luvelta is an antibody-drug conjugate that targets folate receptor alpha (FOLR1) for a subset of acute myeloid leukemia patients, the same target Sutro Biopharma had been pursuing in adult lung and ovarian tumors, as STAT reports. The pediatric signal was a side observation, not a planned line of development, which is part of why no sponsor was positioned to carry it forward. The pharmacology was not why the drug was discontinued. The business case was. The developer reprioritized. The drug was still in a freezer.
Blood Cancer United's president, E. Anders Kolb, has framed the acquisition as a call for systemic change, not a one-off rescue. The policy ask is for clearer regulatory paths to keep investigational therapies alive after a sponsor steps away, shared trial infrastructure so that patient-advocacy groups can run small programs without each one rebuilding the operating manual, and incentives that make it financially possible to keep a drug in development when the original sponsor has walked away, according to STAT. None of that exists today.
A charity is now managing a clinical supply chain because no one else in the system was set up to do it. The supply is finite. The development program is not being restarted. The economics that killed Luvelta are unchanged, and a single nonprofit purchase does not fix them. What it does is buy time for a defined group of children, and it does that by exposing a hole in the drug-development architecture that the next discontinued orphan drug will fall into as surely as this one did.
Whether the Luvelta deal is a precedent or an anomaly is the structural question. If a patient-advocacy group can acquire a discontinued investigational therapy, transfer the IND, and run a compassionate-use program from charitable funding, then other groups may try. Whether the FDA, the original sponsor, and the pharmacy logistics chain will cooperate the same way in every case is not yet clear. The Luvelta deal worked because Blood Cancer United had the relationships, the fundraising capacity, and the staff to execute a complex transfer under time pressure. Most rare-disease patient organizations do not.
What to watch next is whether the FDA issues any guidance on IND transfers and compassionate-use continuity when a sponsor discontinues an active program, and whether any other nonprofit follows Blood Cancer United's lead with a different discontinued asset. The pipeline for orphan drugs produces a steady stream of programs that are scientifically interesting and commercially unviable. The current default is that those programs, and the patients on them, simply end. The Luvelta arrangement is a demonstration that another default is possible. It is also a reminder that the demonstration is being paid for by a charity.